Literature DB >> 19903291

Estimation of sensitivity and specificity of several Trypanosoma cruzi antibody assays in blood donors in Argentina.

Mirta C Remesar1, Cecilia Gamba, Ivana F Colaianni, Mónica Puppo, Paula A Sartor, Edward L Murphy, Torsten B Neilands, María A Ridolfi, M Susana Leguizamón, Silvina Kuperman, Ana E Del Pozo.   

Abstract

BACKGROUND: The absence of a gold standard test for Trypanosoma cruzi antibodies represents a problem not only for the evaluation of screening tests, but also for appropriate blood donor counseling. The aim of this study was to estimate the sensitivity and specificity of multiple blood donor screening tests for T. cruzi antibodies in Argentina. STUDY DESIGN AND METHODS: From June 2006 to March 2007 a sample of 1455 blood donors was recruited from two blood banks in Chaco province, an area of Argentina with highly endemic T. cruzi infection. Samples were tested by three epimastigote lysate enzyme immunoassays (EIAs), one recombinant antigen EIA, two indirect hemagglutination assay (IHA) tests, a particle agglutination assay (PA), and a research trans-sialidase inhibition assay (TIA). Sensitivity and specificity were estimated using latent class analysis (LCA).
RESULTS: LCA estimated the consensus prevalence of T. cruzi infection at 24.5%. Interassay correlation was higher among the four EIA tests and TIA compared to IHA tests. Assay sensitivities varied from 96 to 99.7 for different EIAs, 91% for TIA, 84% for PA, and 66 to 74% for IHA tests. Relative to the LCA, assay specificities were from 96% to almost 100%.
CONCLUSION: Based on the comparison of several tests in a large population from an endemic area for T. cruzi infection, our data showed an adequate sensitivity for EIA tests in contrast to PA and IHA assays. The latter tests should no longer be used for blood donor screening.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903291      PMCID: PMC2841448          DOI: 10.1111/j.1537-2995.2009.02301.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  31 in total

1.  Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme-linked immunosorbent assay kits.

Authors:  D A Leiby; S Wendel; D T Takaoka; R M Fachini; L C Oliveira; M A Tibbals
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  High prevalence of congenital Trypanosoma cruzi infection and family clustering in Salta, Argentina.

Authors:  Olga Sánchez Negrette; María Celia Mora; Miguel Angel Basombrío
Journal:  Pediatrics       Date:  2005-06       Impact factor: 7.124

3.  Control of Chagas disease. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1991

4.  The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region.

Authors:  Marianne Pirard; Naomi Iihoshi; Marleen Boelaert; Paulino Basanta; Freddy López; Patrick Van der Stuyft
Journal:  Transfusion       Date:  2005-04       Impact factor: 3.157

5.  Latent class analysis of diagnostic agreement.

Authors:  J S Uebersax; W M Grove
Journal:  Stat Med       Date:  1990-05       Impact factor: 2.373

6.  Latent variable modeling of diagnostic accuracy.

Authors:  I Yang; M P Becker
Journal:  Biometrics       Date:  1997-09       Impact factor: 2.571

7.  Long-lasting antibodies detected by a trans-sialidase inhibition assay of sera from parasite-free, serologically cured chagasic patients.

Authors:  M S Leguizamón; G Russomando; A Luquetti; A Rassi; M Almirón; S M González-Cappa; A C Frasch; O Campetella
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

8.  Use of trans-Sialidase inhibition assay in a population serologically negative for Trypanosoma cruzi but at a high risk of infection.

Authors:  M S Leguizamón; G Russomando; A Rojas de Arias; M Samudio; M Cabral; S M González-Cappa; A C Frasch; O Campetella
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

9.  Evaluation of three commercial enzyme-linked immunosorbent assays for diagnosis of Chagas' disease.

Authors:  W M Oelemann; M D Teixeira; G C Veríssimo Da Costa; J Borges-Pereira; J A De Castro; J R Coura; J M Peralta
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

10.  Medium scale production and purification to homogeneity of a recombinant trans-sialidase from Trypanosoma cruzi.

Authors:  A Buschiazzo; A C Frasch; O Campetella
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  1996-07       Impact factor: 1.770

View more
  10 in total

1.  Identification of past and recent parvovirus B19 infection in immunocompetent individuals by quantitative PCR and enzyme immunoassays: a dual-laboratory study.

Authors:  Peter A C Maple; Lea Hedman; Pravesh Dhanilall; Kalle Kantola; Visa Nurmi; Maria Söderlund-Venermo; Kevin E Brown; Klaus Hedman
Journal:  J Clin Microbiol       Date:  2014-01-08       Impact factor: 5.948

2.  Enhanced classification of Chagas serologic results and epidemiologic characteristics of seropositive donors at three large blood centers in Brazil.

Authors:  Ester C Sabino; Nanci A Salles; Moussa Sarr; Angela M Barreto; Marcio Oikawa; Cláudia D Oliveira; Silvana C Leao; Anna B Carneiro-Proietti; Brian Custer; Michael P Busch
Journal:  Transfusion       Date:  2010-12       Impact factor: 3.157

3.  Chronic Chagas Disease Diagnosis: A Comparative Performance of Commercial Enzyme Immunoassay Tests.

Authors:  Fred Luciano Neves Santos; Wayner Vieira de Souza; Michelle da Silva Barros; Mineo Nakazawa; Marco Aurélio Krieger; Yara de Miranda Gomes
Journal:  Am J Trop Med Hyg       Date:  2016-03-14       Impact factor: 2.345

4.  Anti-Trypanosoma cruzi inconclusive results in blood donor screening.

Authors:  Márcia Mitiko Otani
Journal:  Rev Bras Hematol Hemoter       Date:  2012

5.  Congenital transmission of Trypanosoma cruzi in non-endemic areas: evaluation of a screening program in a tertiary care hospital in Barcelona, Spain.

Authors:  Susana Otero; Elena Sulleiro; Israel Molina; Maria Espiau; Anna Suy; Andrea Martín-Nalda; Concepción Figueras
Journal:  Am J Trop Med Hyg       Date:  2012-09-17       Impact factor: 2.345

6.  Southern plains woodrats (Neotoma micropus) from southern Texas are important reservoirs of two genotypes of Trypanosoma cruzi and host of a putative novel Trypanosoma species.

Authors:  Roxanne A Charles; Sonia Kjos; Angela E Ellis; John C Barnes; Michael J Yabsley
Journal:  Vector Borne Zoonotic Dis       Date:  2012-11-05       Impact factor: 2.133

Review 7.  Congenital Chagas disease: recommendations for diagnosis, treatment and control of newborns, siblings and pregnant women.

Authors:  Yves Carlier; Faustino Torrico; Sergio Sosa-Estani; Graciela Russomando; Alejandro Luquetti; Hector Freilij; Pedro Albajar Vinas
Journal:  PLoS Negl Trop Dis       Date:  2011-10-25

8.  Diagnostic reliability of an immunochromatographic test for Chagas disease screening at a primary health care centre in a rural endemic area.

Authors:  Diego Mendicino; Mariana Stafuza; Carlina Colussi; Mónica del Barco; Mirtha Streiger; Edgardo Moretti
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-12-02       Impact factor: 2.743

9.  Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina.

Authors:  Diego S Ojeda; María Mora Gonzalez Lopez Ledesma; Horacio M Pallarés; Guadalupe S Costa Navarro; Lautaro Sanchez; Beatriz Perazzi; Sergio M Villordo; Diego E Alvarez; Marcela Echavarria; Kasopefoluwa Y Oguntuyo; Christian S Stevens; Benhur Lee; Jorge Carradori; Julio J Caramelo; Marcelo J Yanovsky; Andrea V Gamarnik
Journal:  PLoS Pathog       Date:  2021-01-14       Impact factor: 6.823

Review 10.  Commercial enzyme-linked immunosorbent assay versuspolymerase chain reaction for the diagnosis of chronic Chagas disease: a systematic review and meta-analysis.

Authors:  Pedro Emmanuel Alvarenga Americano do Brasil; Rodolfo Castro; Liane de Castro
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-01       Impact factor: 2.743

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.